Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835312 | 0.86 | SLC6A2 (0.38) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11625346 | 0.82 | OPRM1 (0.53) | HTR2AOPRM1SLC6A2SLC6A4 | |
| SCHEMBL976310 | 0.82 | SLC6A2 (0.37) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8989069 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4CHRNB2CHRNB4 | |
| SCHEMBL136222 | 0.77 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3458741 | 0.77 | HTR2A (0.48) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL27794398 | 0.77 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1334863 | 0.77 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10880855 | 0.77 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| Bromide SCHEMBL5224748 | 0.76 | HTR2A (0.43) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107129440-B | A kind of total synthesis method of natural products (+)-negamycin | 上海应用技术大学 | 2018-12-04 | — | — | CN | disclosed |
| CN-105814027-A | Novel compounds for the regeneration of terminally differentiated cells and tissues | 阿库西亚医疗有限责任公司 | 2016-07-27 | — | — | CN | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| EP-2217588-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-08-18 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7595315-B2 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
| EP-1716126-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1716126-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005066144-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-0656365-B1 | Substituted 2beta-morpholinoandrostane derivatives | AKZO NOBEL NV (NL) | 1997-04-09 | — | — | EP | disclosed |
| US-5593983-A | PREPARATION BY REACTING SUBSTITUTED /THIO/MORPHOLINE OR SALT AND 2,3-EPOXYANDROSTANE OR 2,3-EPOXY-19-NOR-ANDROSTANE; USE TO INDUCE ANESTHESIA | AKZO NOBEL N.V. (NL) | 1997-01-14 | — | — | US | disclosed |
| EP-0656365-A1 | Substituted 2beta-morpholinoandrostane derivatives | Akzo Nobel N.V. (NL) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | HTR2A 1799/4885OPRM1 489/4885SLC6A2 3198/4885 |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | HTR2A 436/4885OPRM1 431/4885SLC6A2 1262/4885 |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | HTR2A 44/4885OPRM1 9/4885SLC6A2 1/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | HTR2A 1799/4885OPRM1 489/4885SLC6A2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.